Literature DB >> 26280001

Biomarkers and Personalized Sorafenib Therapy.

M Kudo1.   

Abstract

Entities:  

Year:  2014        PMID： 26280001      PMCID： PMC4531426          DOI： 10.1159/000343870

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  26 in total

1.  Increased MAPK expression and activity in primary human hepatocellular carcinoma.

Authors:  C M Schmidt; I H McKillop; P A Cahill; J V Sitzmann
Journal:  Biochem Biophys Res Commun       Date:  1997-07-09       Impact factor: 3.575

2.  Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.

Authors:  Koji Miyahara; Kazuhiro Nouso; Takeshi Tomoda; Sayo Kobayashi; Hiroaki Hagihara; Kenji Kuwaki; Junichi Toshimori; Hideki Onishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto
Journal:  J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 4.029

Review 3.  Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.

Authors:  Masatoshi Kudo; Kazuomi Ueshima
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

4.  Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.

Authors:  Bassam Estfan; Michael Byrne; Richard Kim
Journal:  Am J Clin Oncol       Date:  2013-08       Impact factor: 2.339

5.  Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Authors:  Bruno Vincenzi; Daniele Santini; Antonio Russo; Raffaele Addeo; Francesco Giuliani; Liliana Montella; Sergio Rizzo; Olga Venditti; Anna Maria Frezza; Michele Caraglia; Giuseppe Colucci; Salvatore Del Prete; Giuseppe Tonini
Journal:  Oncologist       Date:  2010-01-05

6.  c-met mRNA overexpression in human hepatocellular carcinoma.

Authors:  L Boix; J L Rosa; F Ventura; A Castells; J Bruix; J Rodés; R Bartrons
Journal:  Hepatology       Date:  1994-01       Impact factor: 17.425

7.  Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

Authors:  Thomas Yau; Pierre Chan; Kelvin K Ng; Sin Ho Chok; Tan To Cheung; Sheung Tat Fan; Ronnie T Poon
Journal:  Cancer       Date:  2009-01-15       Impact factor: 6.860

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.

Authors:  S Hagiwara; M Kudo; T Nagai; T Inoue; K Ueshima; N Nishida; T Watanabe; T Sakurai
Journal:  Br J Cancer       Date:  2012-05-17       Impact factor: 7.640

10.  Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.

Authors:  Tadaaki Arizumi; Kazuomi Ueshima; Haruhiko Takeda; Yukio Osaki; Masahiro Takita; Tatsuo Inoue; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Naoshi Nishida; Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2014-02-06       Impact factor: 7.527
View more
  13 in total

1.  Immune Checkpoint Blockade in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-10-15       Impact factor: 11.740

2.  Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe.

Authors: 
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

Review 3.  Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.

Authors:  Julien Edeline; Marine Gilabert; Etienne Garin; Eveline Boucher; Jean-Luc Raoul
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

4.  Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.

Authors:  Satoshi Narahara; Takehisa Watanabe; Katsuya Nagaoka; Nahoko Fujimoto; Yoki Furuta; Kentaro Tanaka; Takayuki Tokunaga; Takeshi Kawasaki; Yoko Yoshimaru; Hiroko Setoyama; Kentaro Oniki; Junji Saruwatari; Masakuni Tateyama; Hideaki Naoe; Motohiko Tanaka; Yasuhito Tanaka; Yutaka Sasaki
Journal:  Hepatol Commun       Date:  2021-11-27

5.  Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.

Authors:  Wei Chen; Weikai Xiao; Kunsong Zhang; Xiaoyu Yin; Jiaming Lai; Lijian Liang; Dong Chen
Journal:  Sci Rep       Date:  2016-03-11       Impact factor: 4.379

Review 6.  Systemic treatment for hepatocellular carcinoma: Still unmet expectations.

Authors:  Dimitrios N Samonakis; Elias A Kouroumalis
Journal:  World J Hepatol       Date:  2017-01-18

7.  Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience.

Authors:  Carsten Meyer; Claus Christian Pieper; Hojjat Ahmadzadehfar; Nina Alexandra Lampe; Eva Maria E Matuschek; Thomas Adrian Maschke; Simon Jonas Enkirch; Markus Essler; Ulrich Spengler; Hans Heinz Schild
Journal:  Onco Targets Ther       Date:  2017-09-26       Impact factor: 4.147

8.  Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.

Authors:  Toshiharu Sakurai; Norihisa Yada; Satoru Hagiwara; Tadaaki Arizumi; Kosuke Minaga; Ken Kamata; Mamoru Takenaka; Yasunori Minami; Tomohiro Watanabe; Naoshi Nishida; Masatoshi Kudo
Journal:  Cancer Sci       Date:  2017-09-02       Impact factor: 6.716

9.  Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma.

Authors:  Janine Rennert; Isabel Wiesinger; Andreas Schicho; Lukas Philip Beyer; Philipp Wiggermann; Christian Stroszczynski; Ernst Michael Jung
Journal:  PLoS One       Date:  2019-06-10       Impact factor: 3.240

10.  Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib.

Authors:  Piero Colombatto; Coskun Ozer Demirtas; Gabriele Ricco; Luigi Civitano; Piero Boraschi; Paola Scalise; Daniela Cavallone; Filippo Oliveri; Veronica Romagnoli; Patrizia Bleve; Barbara Coco; Antonio Salvati; Lucio Urbani; Ferruccio Bonino; Maurizia Rossana Brunetto
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.